A Study of VIRTUGUIDE System and DePuy Synthes Lapidus Implant in Participants Undergoing Lapidus Procedure
VIRTUGUIDE™ SYSTEM REGISTRY
The purpose of this study is to assess the surgeon experience and surgery outcomes in participants undergoing index Lapidus procedure for the correction of hallux valgus (a foot deformity where the big toe angles outward towards the other toes, causing a painful bony bump at the base of the big toe joint) using the VIRTUGUIDE System and compatible DePuy Synthes Lapidus implants.
調査の概要
状態
条件
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Marcie Maichle
- 電話番号:443-987-0665
- メール:MMaichle@ITS.JNJ.com
研究連絡先のバックアップ
- 名前:Priyamvada Devineni
- メール:pdevinen@its.jnj.com
研究場所
-
-
Iowa
-
Waterloo、Iowa、アメリカ、50703
- 募集
- MercyOne Waterloo Medical Center
-
West Des Moines、Iowa、アメリカ、50266
- 募集
- The Iowa Clinic
-
-
Michigan
-
Warren、Michigan、アメリカ、48092
- 募集
- Foot And Ankle Specialists of Southeast Michigan
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28207
- 募集
- OrthoCarolina Research Institute
-
-
Virginia
-
Virginia Beach、Virginia、アメリカ、23462
- 募集
- Atlantic Orthopaedic Specialists
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population will include adults who will undergo surgical treatment for the correction of hallux valgus via Lapidus procedure using the VIRTUGUIDE System and will receive a compatible DePuy Synthes Lapidus implant.
説明
Inclusion criteria:
- Participants, both male and female, >= 22 years old at the time of consent
- Participants undergoing a primary Lapidus procedure for the correction of hallux valgus using the VIRTUGUIDE System (software + instruments) and who receive a compatible DePuy Synthes Lapidus implant
- Participants must be able to read and understand questions and responses in an available translated language for patient reported outcomes (PROMs)
- All primary Lapidus fixation implants are used on-label according to the implant IFU/FDA cleared labeling
- Participants who can speak, read, and comprehend the Institutional Review Board approved Informed Consent Document and are willing and able to provide informed patient consent for participation and have authorized the transfer of his/her information to DePuy Synthes
Exclusion criteria:
- Participation in any other medical device or medicinal product study within the previous month. Participation in observational studies is allowed
- In the opinion of the Principal Investigator, the subject is unable to comply with the requirements of the registry
- Participant has known allergies to implant components
- Participant presenting for a revision of a Lapidus procedure
- Participant has existing hardware in the operative joint
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
VIRTUGUIDE System and Compatible DePuy Synthes Lapidus Implant(s)
Participants with hallux valgus undergoing index Lapidus procedure using the VIRTUGUIDE System and compatible DePuy Synthes Lapidus implant(s) will be enrolled in the study. All participants will be followed up as per the surgeon's standard of care for up to 12 months after the surgery. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Radiographic Documentation of Fusion/Healing Status
時間枠:Up to 12 months post-procedure
|
Evaluation of healing, that is, healing will be a combination of radiographic and clinical assessment. Healing (fusion) will be considered achieved based on surgeon interpretation of radiographic images, lack of clinical motion and no pain at the fused site indicative of failed fusion. Imaging, whether X-ray or computed tomography (CT) collected per standard of care (SOC), utilized for radiographic assessment will be collected. |
Up to 12 months post-procedure
|
|
Patient Reported Outcome Measures (PROM): Manchester Oxford Foot Questionnaire (Quality of Life Index) Scores
時間枠:Up to 12 months post-procedure
|
The Manchester Oxford Foot Questionnaire (MOxFQ) with three domains (walking/standing, pain, and social interaction) is a standardized instrument developed and validated specifically for hallux valgus (bunions) corrective surgery. It is widely regarded as the gold standard for content and construct validity. It is designed for self (participant) completion and consists of sixteen (16) questions all of which are scored on a five (5) item Likert scale. The scores for each domain range from 0-100, with 100 representing the worst condition. |
Up to 12 months post-procedure
|
|
PROM: Numeric Pain Rating Scale Scores
時間枠:Up to 12 months post-procedure
|
The Numeric Pain Rating Scale is a three (3) question self-administered PROM with a 10-point one-dimensional line anchored on either end by verbal descriptors ranging from "no pain" to "worst imaginable pain". The higher score indicates greater pain intensity. The three questions ask the participant to indicate the intensity of current, best, and worst pain levels over the past 24 hours. |
Up to 12 months post-procedure
|
|
Number of Participants Reporting any Perioperative Adverse Event (AE)
時間枠:Up to 12 months post-procedure
|
An AE is any untoward medical occurrence (sign, symptom, or disease) in a participant that is deemed at least possibly related to the DePuy Synthes registry device, or any adjunctive implant device used during the index procedure. |
Up to 12 months post-procedure
|
|
Number of Participants with AEs Related to Device/Procedure
時間枠:Up to 12 months post-procedure
|
An AE is any untoward medical occurrence (sign, symptom, or disease) in a participant that is deemed at least possibly related to the DePuy Synthes registry device, or any adjunctive implant device used during the index procedure. The determination of whether the AE is related to the device and/or procedure will be based upon whether a causal relationship between the device and/or procedure and the AE is at least a reasonable possibility, i.e., the relationship cannot be ruled out. A causal relationship cannot be ruled out if, in the medical judgment of the Investigator, the effect follows a reasonable temporal association with the use of the device and/or is confirmed by the improvement of the effect upon discontinuation of the clinical use of the device, and/or the effect is not reasonably explained by the participant's clinical state. |
Up to 12 months post-procedure
|
|
Number of Participants with Serious Adverse Events (SAEs)
時間枠:Up to 12 months post-procedure
|
SAEs are AEs defined as having one or more of the following outcomes: death, serious deterioration in the health of the subject that has resulted in a. life-threatening illness or injury b. permanent impairment of a body structure or a body function c. hospitalization or prolongation of existing hospitalization d. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function e. chronic disease and Fetal distress, fetal death or a congenital physical or mental impairment or birth defect. |
Up to 12 months post-procedure
|
|
Number of Participants Reporting Device Deficiency
時間枠:Up to 12 months post-procedure
|
Device deficiencies include malfunctions, use errors, and inadequate labeling. Device malfunctions are failures of the device to perform as intended and can be defined as issues with software (VIRTUGUIDE Pre-Planning Software), any breakage, malposition, migration, and/or loosening of the device. |
Up to 12 months post-procedure
|
|
Number of Participants who Underwent Revision
時間枠:Up to 12 months post-procedure
|
Revision is defined as surgery following the index Lapidus procedure that involves adjustment, modification, removal, or replacement of the implanted device. Surgeries involving adjunctive implants at the first metatarsal-cuneiform joint are considered as a revision. |
Up to 12 months post-procedure
|
|
Number of Participants who Underwent Reoperation
時間枠:Up to 12 months post-procedure
|
Reoperation is defined as any subsequent surgical procedure performed following the index surgery that does not involve adjustment, modification, removal, or replacement of the primary Lapidus implant(s), nor the addition of adjunctive fixation at the first metatarsal-cuneiform joint. |
Up to 12 months post-procedure
|
|
Number of Participants Reporting Recurrence
時間枠:Up to 12 months post-procedure
|
Radiographic recurrence will be considered to have occurred in those subjects with correction if both of the following criteria are met: Intermetatarsal Angle (IMA) of greater than (>)12 degree and Hallux Valgus Angle (HVA) > 15 degree. |
Up to 12 months post-procedure
|
協力者と研究者
捜査官
- スタディディレクター:DePuy Synthes Products, Inc. Clinical Trial、DePuy Synthes Products, Inc.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。